Mitoxantrone is superior to liposomal daunorubicin in MRD (measurable residual disease)-guided treatment of AML in pediatric cases
1. Mitoxantrone enhances five-year event-free survival over liposomal daunorubicin in MRD-guided pediatric AML treatment. 2.High-risk patients identified by MRD guidance ...